This site is intended for health professionals only

Novel approach to osteoarthritis treatment launched


Pro Bono Bio™ has announced the launch of Flexiseq™, a unique approach to the treatment of osteoarthritis (OA) in the UK.

The new pharmaceutical company plans to launch Flexiseq in Germany in October and other European markets will be phased in over the next two years.

Extensive clinical trials have shown that Flexiseq is clinically effective in treating OA pain.

A European Phase III trial completed in 2009, involving 698 patients in the three arms (Flexiseq, celecoxib and the placebo), showed that Flexiseq is as effective as the leading prescribed COX-2 product for patients suffering pain caused by osteoarthritis.

It is estimated that there are over 80 million osteoarthritis sufferers in Western Europe and the Commonwealth of Independent States (CIS), around half of whom are diagnosed and who may be looking for improved options to treat their osteoarthritis.

Clinical trials in over 1,000 patients have shown that Flexiseq is both efficacious and well tolerated.

The only side effects attributed to the product have been transient, localised skin irritations, experienced by a small proportion of the patients.

Flexiseq has also been used alongside oral non-steroidal anti-inflammatory drugs (NSAIDS) without adding to their side effects.  These promising results have been demonstrated for treatment periods of up to a year.

Flexiseq is available as a gel that contains absorbing microstructures, called Sequessomes, which are able to cross the skin and reach the site of pain.

Sequessomes physically absorb and remove chemicals that are a key component in the pain and inflammation cascade. Flexiseq provides a localised, soothing effect on joint pain.

Flexiseq’s novel mode of action allows it to be used either alone or in conjunction with the patient’s existing osteoarthritis treatment regime.

“Leading Rheumatologists are concerned about the limited treatments available for OA sufferers and also about the side effects of some existing therapies,” said Michael Earl, Chief Operating Officer of Pro Bono Bio.

“Flexiseq is an important part of the answer to these concerns.  Its launch has been kept secret to coincide with the launch of Pro Bono Bio. Now the secret is out we are expecting Flexiseq to draw a lot of attention from physicians and patient groups.”

Pro Bono Bio

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine